About

About Sio

Sio Gene Therapies is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease.

Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.

Our mission is simple:

To combine cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. We are working tirelessly to advance our rare fatal pediatric neurodegenerative programs through clinical development so that patients can access the therapies they need.

Management & Board of Directors

David Nassif, JD

David Nassif, JD

Chief Executive Officer, Chief Financial Officer, General Counsel and member of the Board of Directors

David Nassif, JD

Chief Executive Officer, Chief Financial Officer, General Counsel and member of the Board of Directors

David Nassif, JD, serves as Chief Executive Officer, Chief Financial Officer and General Counsel at Sio. He has more than 25 years of life sciences industry experience in executive financial management roles in development-stage, commercial-stage, public and private companies. Prior to joining Sio, Mr. Nassif was Executive Vice President and Chief Financial Officer of SteadyMed Therapeutics, where he was instrumental in its acquisition by United Therapeutics in August 2018. From 2011 to 2014, Mr. Nassif served as the President and Chief Financial Officer of Histogen. Previously, he was Executive Vice President and Chief Financial Officer of Zogenix and held several key roles at Amphastar Pharmaceuticals and RealAge Inc. Earlier in his career, Mr. Nassif held various positions with Cypros Pharmaceuticals, where he was instrumental in leading its merger with Ribogene, Inc. to form Questcor Pharmaceuticals, Inc. He holds a BS in finance and management information systems with honors from the University of Virginia and a JD from the University of Virginia School of Law.

Scroll to Top